# Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

> **NCT07071155** · EARLY_PHASE1 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 18 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Overlap Neoplasms
- Chronic Neutrophilic Leukemia

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT07071155
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-19
- **Primary completion:** 2028-03-05
- **Final completion:** 2028-07-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07071155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07071155, "Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07071155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*